Tag: Survival

And risk for posttransplant death decreasing despite drug overdose, hepatitis C-positive donors contributing to donor risk

Limited or no improvement seen in female breast cancer, cervical cancer, ovarian cancer, and bone and joint sarcomas

Although nearly all metrics improved for racial-ethnic minorities, recent breast cancer-related mortality in Florida still higher in Black women

Survival better compared with colon cancer patients in the general U.S. population, overall and in subgroups including Black versus White race

Survival advantage greatest for diagnosis at age 35 through 39 years with stage I or II disease versus diagnosis at age 51 to 55 years

Survival improved across calendar periods for all age groups except for patients aged ≥70 years

Three- and five-year overall survival similar with allogeneic or autologous HSCT, but transplant-related mortality higher with allogeneic HSCT

Hardships include forgoing care and medication nonadherence due to cost

Baseline body mass index tied to outcomes, with obesity linked to poorer outcome

Validated international prognostic index stratifies patients according to low, intermediate, high risk